share_log

Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $45 Price Target

Moomoo 24/7 ·  Apr 12 09:55

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $45 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment